Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

Sa Rang Kim; Alexandra Charos; William Damsky; Peter Heald; Michael Girardi; Brett A King

doi:10.1016/j.jdcr.2017.12.003

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

JAAD Case Rep. 2018 Apr 30;4(5):443-445. doi: 10.1016/j.jdcr.2017.12.003. eCollection 2018 Jun.

Authors

Sa Rang Kim¹, Alexandra Charos¹, William Damsky², Peter Heald², Michael Girardi², Brett A King²

Affiliations

¹ Yale School of Medicine, New Haven, Connecticut.
² The Department of Dermatology, Yale University, New Haven, Connecticut.

No abstract available

Keywords: ECP, extracorporeal photopheresis; EF, eosinophilic fasciitis; GDM, generalized deep morphea; HES, hypereosinophilic syndrome; IL, interleukin; JAK, Janus kinase; JAK-STAT; Janus kinase; Janus kinase inhibitor; ROM, range of motion; TGF-β, transforming growth factor beta; eosinophilic fasciitis; interleukin-4; morphea; tofacitinib; transforming growth factor-β.

Publication types

Case Reports

Grants and funding

T32 CA193200/CA/NCI NIH HHS/United States